鉴于此，ROR1被认为是具有广谱抗癌潜力的新药靶点，在全球范围内，开发方向包括单抗、双抗、CAR-T、ADC。但目前尚无ROR1靶点药物获批上市，Oncternal开发的ROR1单抗Zilovertamab是进展最快的药物，此前已经在血液瘤适应症上开展了联用伊布替尼的临床三期研究（ZILO-301）。即便目前该研究由于BTK抑制剂竞争格局的变化...
鉴于此,ROR1被认为是具有广谱抗癌潜力的新药靶点,在全球范围内,开发方向包括单抗、双抗、CAR-T、ADC。 但目前尚无ROR1靶点药物获批上市,Oncternal开发的ROR1单抗Zilovertamab是进展最快的药物,此前已经在血液瘤适应症上开展了联用伊布替尼的临床三期研究(ZILO-301)。 即便目前该研究由...
Another ROR1-targeting therapy which has been tested in clinical trials is the immunotherapy called ROR1 chimeric antigen receptor (CAR)-T cell therapy48. A phase I trial (NCT02706392) is currently recruiting ROR1 positive cancers such as CLL and triple negative breast carcinoma. These new ...
cell therapy in R/R B-cell ALL and expecting promising results [144,145]. Currently, for MCL, Brexucabtagene autoleucel is approved as a CAR T cell therapy, with a very good overall survival, while Lisocabtagene maraleucel is in phase one clinical trial and shows promising results [...
目前,已有多款产品获批MCL适应症,除了Gilead旗下KitePharm的Tecartus (Brexucabtagene autoleucel)为CAR-T疗法外,其余均为小分子药物。 CLL 慢性淋巴细胞白血病(CLL)是最常见的成人白血病。它的特点是血液、骨髓和淋巴组织中CD5+的成熟B细胞的异常扩增。...
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. Lyell is currently enrolling a Phase 1 clinical trial evaluating a first-generation ROR1-targeted CAR T-cell therapy enhanced with anti-exhaustion technology in patien...
18 More importantly, results of a phase 1 clinical trial with ROR1-specific CAR-T cells based off of the ROR1-2A2 antibody epitope in triple-negative breast and non–small cell lung cancer found no dose-limiting toxicities after infusions of up to 1 × 107 ROR1 CAR-T cells.16 Because ...
This phase II trial evaluated the efficacy of ESK981 as a single agent in patients w... EI Heath,W Chen,L Heilbrun,... - 《Investigational New Drugs》 被引量: 0发表: 2024年 Abstract 1789: Pre-clinical studies to advance anti-ROR1 CAR-T cell therapy for metastatic prostate cancer WNT...
reported that T cells modified with an optimized ROR1-CAR have signifi- cant antitumor efficacy in a preclinical model in vivo, and the clinical study is about to be started36. There were some reports about ROR1 expression in lung cancer, but most data were based on cellular and animal ...
Therefore, as an alternative to the previous strategies, the present invention provides with ROR1 specific CARs, which can be expressed in immune cells to target ROR1 malignant cells with significant clinical advantage. The inventors have found that, by combining CAR architecture to the choice of ...